PHARMACOLOGY OF LOW-MOLECULAR-WEIGHT HYDROXYETHYLSTARCHES

被引:10
|
作者
BARON, JF
机构
来源
关键词
D O I
10.1016/S0750-7658(05)80756-7
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
In the last ten years, the practice of plasma volume expansion has changed significantly. Most clinicans have put a stop to the use of fresh frozen plasma because of growing concerns about hepatitis and AIDS transmission. Today, natural and synthetic colloids and crystalloids are used to a great extent. Although clinical practice varies from one institution to another, the most widely observed change was a major increase in the administration of human serum albumin (HSA). As a result, the cost of plasma volume expansion became so high that it justified finding safe and cheaper alternatives to HSA. Low molecular weight. hydroxyethylstarches (HES) are the synthetic colloids which are closest to HSA. HES are modified natural polymers whose physico-chemical properties are defined by their molecular weight and molar substitution ratio. Average molecular weights of these polydispersed solutions are approximately 200 to 250 kd (in weight) and 60 kd (in number). Hydroxyethylation, which slows down hydrolysis by alpha-amylase, is best quantified by the molar substitution ratio between the proportions of hydroxyethylether and glucose. HES have pharmacokinetic properties which are independent of molecular weight and directly related to the molar substitution ratio. The two HES available in France are Elohes(R) and Lomol(R), Elohes(R). at a concentration of 6%, has a colloid-osmotic effect close to that of plasma. It induces an initial plasma volume expansion greater than that of the infused volume, and has a long lasting effect (24 h) related to its molar substitution ratio (0.62). Lomol , at a concentration of 10% is hyperoncotic. Its initial effect is greater than that of Elohes(R), but it is eliminated more rapidly because its lower molar susbtitution ratio (0.45). The good tolerance to these products is also an advantage in comparison with the other colloids.
引用
收藏
页码:509 / 515
页数:7
相关论文
共 50 条
  • [41] Viscoelasticity of Low-Molecular-Weight Polyelectrolytes
    Bonnaud, Patrick A.
    Ushiyama, Hiroshi
    Tejima, Syogo
    Fujita, Jun-Ichi
    JOURNAL OF PHYSICAL CHEMISTRY B, 2022, 126 (26): : 4899 - 4913
  • [42] LOW-MOLECULAR-WEIGHT NUCLEAR RNAS
    BUSCH, H
    ROCHOI, TS
    PRESTAYKO, AW
    SHIBATA, H
    CROOKE, ST
    ELKHATIB, SM
    CHOI, YC
    MAURITZEN, CM
    PERSPECTIVES IN BIOLOGY AND MEDICINE, 1971, 15 (01) : 117 - +
  • [43] Perioperative low-molecular-weight heparin
    Carter, S
    JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 1996, 78B (01): : 167 - 167
  • [44] Low-molecular-weight heparins - reply
    Weitz, JI
    NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (10): : 687 - 688
  • [45] LOW-MOLECULAR-WEIGHT HEPARIN IN HEMODIALYSIS
    DEUBER, HJ
    SCHULZ, W
    KLINISCHE WOCHENSCHRIFT, 1987, 65 (20): : 992 - 992
  • [46] LOW-MOLECULAR-WEIGHT HEPARINS AND HYPOALDOSTERONISM
    LEVESQUE, H
    VERDIER, S
    CAILLEUX, N
    ELIELEGRAND, MC
    GANCEL, A
    BASUYAU, JP
    BORG, JY
    MOORE, N
    COURTOIS, H
    BRITISH MEDICAL JOURNAL, 1990, 300 (6737): : 1437 - 1438
  • [47] Uses of low-molecular-weight heparin
    Bounameaux, H
    Goldhaber, SZ
    BLOOD REVIEWS, 1995, 9 (04) : 213 - 219
  • [48] Low-molecular-weight heparins:: Are they interchangeable?
    van der Heijden, JF
    Prins, MH
    Büller, HR
    HAEMOSTASIS, 2000, 30 : 148 - 157
  • [49] Low-molecular-weight heparin for thromboprophylaxis
    Camporese, Giuseppe
    Bernardi, Enrico
    CURRENT OPINION IN PULMONARY MEDICINE, 2009, 15 (05) : 443 - 454
  • [50] STRUCTURE OF LOW-MOLECULAR-WEIGHT CHONDROITINSULFATE
    NAGGI, A
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 1993, 13 : 19 - 26